BillionToOne Q4 rev $96.1M (+113% YoY); net income $4.4M; raises FY26 guidance

BillionToOne, Inc.

Q4 revenue $96.1M (+113% YoY); net income $4.4M ($0.11 diluted) vs loss of $11.5M.
FY2025 revenue $305.1M (+100%); operating income $16.0M vs loss of $47.1M in 2024.
Raised FY2026 revenue guidance to $430-$445M (41-46% growth) from prior $415-$430M.
Gross margin improved to 71% in Q4 (from 57%) and 68% for FY (from 53%).
Launched new prenatal (RBC/platelet NIPT) and oncology (Northstar PGx/CH) tests in Q1 2026.

item 2.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BillionToOne, Inc. updated its the fourth quarter ended December 31, 2025 guidance (raised).

Period: the fourth quarter ended December 31, 2025
Guidance: raised
Result: reported results

Exact text from the filing

On March 4, 2026 , BillionToOne, Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BillionToOne, Inc. updated its the year ended December 31, 2025 guidance (raised).

Period: the year ended December 31, 2025
Guidance: raised
Result: reported results

Exact text from the filing

On March 4, 2026 , BillionToOne, Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

334 earnings releases filed in the last 30 days. Browse all earnings releases →

BillionToOne, Inc. filing history →

Source: SEC EDGAR

accession 0002070849-26-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.